Cargando…

Cell Transfer Therapy for Cancer: Past, Present, and Future

Cell transfer therapy for cancer has made a rapid progress recently and the immunotherapy has been recognized as the fourth anticancer modality after operation, chemotherapy, and radiotherapy. Lymphocytes used for cell transfer therapy include dendritic cells, natural killer (NK) cells, and T lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xiaoling, Wang, Xian, Jin, Hongchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987872/
https://www.ncbi.nlm.nih.gov/pubmed/24741604
http://dx.doi.org/10.1155/2014/525913
_version_ 1782311944162639872
author Qian, Xiaoling
Wang, Xian
Jin, Hongchuan
author_facet Qian, Xiaoling
Wang, Xian
Jin, Hongchuan
author_sort Qian, Xiaoling
collection PubMed
description Cell transfer therapy for cancer has made a rapid progress recently and the immunotherapy has been recognized as the fourth anticancer modality after operation, chemotherapy, and radiotherapy. Lymphocytes used for cell transfer therapy include dendritic cells, natural killer (NK) cells, and T lymphocytes such as tumor-infiltrating lymphocytes (TILs) and cytotoxic T lymphocytes (CTLs). In vitro activated or engineered immune cells can traffic to cancer tissues to elicit persistent antitumor immune response which is very important especially after immunosuppressive treatments such as chemotherapy. In this review, we overviewed recent advances in the exploration of dendritic cells, NK cells, and T cells for the treatment of human cancer cells.
format Online
Article
Text
id pubmed-3987872
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39878722014-04-16 Cell Transfer Therapy for Cancer: Past, Present, and Future Qian, Xiaoling Wang, Xian Jin, Hongchuan J Immunol Res Review Article Cell transfer therapy for cancer has made a rapid progress recently and the immunotherapy has been recognized as the fourth anticancer modality after operation, chemotherapy, and radiotherapy. Lymphocytes used for cell transfer therapy include dendritic cells, natural killer (NK) cells, and T lymphocytes such as tumor-infiltrating lymphocytes (TILs) and cytotoxic T lymphocytes (CTLs). In vitro activated or engineered immune cells can traffic to cancer tissues to elicit persistent antitumor immune response which is very important especially after immunosuppressive treatments such as chemotherapy. In this review, we overviewed recent advances in the exploration of dendritic cells, NK cells, and T cells for the treatment of human cancer cells. Hindawi Publishing Corporation 2014 2014-01-09 /pmc/articles/PMC3987872/ /pubmed/24741604 http://dx.doi.org/10.1155/2014/525913 Text en Copyright © 2014 Xiaoling Qian et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Qian, Xiaoling
Wang, Xian
Jin, Hongchuan
Cell Transfer Therapy for Cancer: Past, Present, and Future
title Cell Transfer Therapy for Cancer: Past, Present, and Future
title_full Cell Transfer Therapy for Cancer: Past, Present, and Future
title_fullStr Cell Transfer Therapy for Cancer: Past, Present, and Future
title_full_unstemmed Cell Transfer Therapy for Cancer: Past, Present, and Future
title_short Cell Transfer Therapy for Cancer: Past, Present, and Future
title_sort cell transfer therapy for cancer: past, present, and future
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987872/
https://www.ncbi.nlm.nih.gov/pubmed/24741604
http://dx.doi.org/10.1155/2014/525913
work_keys_str_mv AT qianxiaoling celltransfertherapyforcancerpastpresentandfuture
AT wangxian celltransfertherapyforcancerpastpresentandfuture
AT jinhongchuan celltransfertherapyforcancerpastpresentandfuture